Publications and Posters - Affimed

All categories

Publications

Posters

All Cell Engagers

AFM11

AFM13

AFM24

AFM26

AFM28

All years

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

A Phase 1 Study Investigating the Combination of AFM13 and the Monoclonal Anti-PD-1 Antibody Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data

Bartlett et al.
23rd Congress of EHA – AFM13

CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells

Pahl et al.
Cancer Immunol Res 2018; 6:517-527.

link to publication

Pharmacokinetics and in vitro/in vivo characterization of high-affinity bispecific EGFR/CD16A NK cell engagers for the treatment of EGFR-expressing tumors

Kluge et al.
AACR 2018 – AFM24

Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy.

J. Koch, M. Tesar
Transfus Med Hemother 2017; 44:337-350.

link to publication

Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells.

Gantke et al.
Protein Eng Des Sel. 2017 Aug 17:1-12. doi: 10.1093/protein/gzx043.

link to publication

AFM26 – Targeting BCMA for NK cell-mediated immunotherapy of multiple myeloma

Gantke et al.
ASH 2017 – AFM26

A Phase 1 Study Investigating the Combination of AFM13 and the Monoclonal Anti-PD-1 Antibody Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Data from the Dose Escalation Part of the Study

Ansell et al.
ASH 2017 – AFM13

AFM26: A first-in-class, high affinity bispecific NK-cell engager targeting BCMA to treat multiple myeloma

Gantke et al.
EACR-AACR-SIC 2017 Special Conference

High affinity bispecific EGFR/CD16A antibodies specifically recruit NK-cells to target EGFR-expressing tumors

Kluge et al.
EACR-AACR-SIC 2017 Special Conference

AFM26 is a novel, highly potent BCMA/CD16A-directed bispecific antibody for high affinity NK-cell engagement in multiple myeloma

Gantke et al.
ASCO 2017 AFM26

1
2
3
4
5
6
7
8